BIOMX INC (PHGE) Stock Price & Overview
NYSEARCA:PHGE • US09090D5095
Current stock price
The current stock price of PHGE is 1.465 USD. Today PHGE is up by 0.34%. In the past month the price decreased by -68.53%. In the past year, price decreased by -87.42%.
PHGE Key Statistics
- Market Cap
- 11.486M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -23.56
- Dividend Yield
- N/A
PHGE Stock Performance
PHGE Stock Chart
PHGE Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to PHGE. When comparing the yearly performance of all stocks, PHGE is a bad performer in the overall market: 98.8% of all stocks are doing better.
PHGE Earnings
PHGE Forecast & Estimates
8 analysts have analysed PHGE and the average price target is 168.3 USD. This implies a price increase of 11388.05% is expected in the next year compared to the current price of 1.465.
PHGE Groups
Sector & Classification
PHGE Financial Highlights
Over the last trailing twelve months PHGE reported a non-GAAP Earnings per Share(EPS) of -23.56. The EPS decreased by -180.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -625.96% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHGE Ownership
PHGE Latest News, Press Relases and Analysis
PHGE Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.51 | 362.808B | ||
| AMGN | AMGEN INC | 15.04 | 186.117B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 165.442B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.44 | 111.051B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.81 | 79.011B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.58 | 41.154B | ||
| INSM | INSMED INC | N/A | 30.431B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.508B | ||
| NTRA | NATERA INC | N/A | 29.114B | ||
| BIIB | BIOGEN INC | 11.77 | 27.29B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.71 | 25.135B | ||
| MRNA | MODERNA INC | N/A | 21.507B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.454B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PHGE
Company Profile
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Company Info
IPO: 2018-12-18
BIOMX INC
22 Einstein St., Floor 4
Ness Ziona MARYLAND 7414002 IL
CEO: Jonathan Solomon
Employees: 20
Phone: 972723942377
BIOMX INC / PHGE FAQ
What does PHGE do?
BiomX, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. The firm is focused on developing both natural and engineered phage therapies. The company develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The firm discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
What is the stock price of BIOMX INC today?
The current stock price of PHGE is 1.465 USD. The price increased by 0.34% in the last trading session.
Does PHGE stock pay dividends?
PHGE does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHGE stock?
PHGE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What do analysts say about BIOMX INC (PHGE) stock?
8 analysts have analysed PHGE and the average price target is 168.3 USD. This implies a price increase of 11388.05% is expected in the next year compared to the current price of 1.465.
Would investing in BIOMX INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on PHGE.